Denali Therapeutics Reports Increased Losses Amid Strategic Collaborations

Denali Therapeutics ( (DNLI) ) has released its Q3 earnings. Here is a breakdown of the information Denali Therapeutics presented to its investors.

Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing therapeutics for neurodegenerative and lysosomal storage diseases, headquartered in South San Francisco, California. The latest earnings report for Denali Therapeutics reveals a challenging financial period, with the company reporting a net loss of $126.9 million for the third quarter of 2025, compared to a net loss of $107.2 million in the same period last year. The company’s total operating expenses increased to $137.4 million, primarily driven by research and development costs. Despite the losses, Denali maintains a strong cash position with $90.9 million in cash and cash equivalents and $757.2 million in short-term marketable securities. The company also highlighted its ongoing collaborations, including those with Biogen and Sanofi, which continue to play a crucial role in its strategic development plans. Looking ahead, Denali Therapeutics remains committed to advancing its pipeline of innovative therapies, with management expressing cautious optimism about future milestones and potential market opportunities.